Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10377737" target="_blank" >RIV/00216208:11140/18:10377737 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/18:10377737

Result on the web

<a href="https://doi.org/10.1097/MEG.0000000000001084" target="_blank" >https://doi.org/10.1097/MEG.0000000000001084</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MEG.0000000000001084" target="_blank" >10.1097/MEG.0000000000001084</a>

Result language

angličtina

Original language name

Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

Original language description

BackgroundThere is lack of evidence to guide the type, intensity, and the duration of anticoagulation following venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD).Patients and methodsRegistro Informatizado Enfermedad Trombo Embolica (RIETE) is an ongoing, multicenter, observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE. We used the RIETE database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in noncancer patients with or without IBD.ResultsAs of October 2014, 41927 patients without active cancer have been recruited in RIETE. Of these, 265 (0.63%) had IBD and 85 (32%) had the VTE during an acute flare. The duration of anticoagulation was similar in patients with VTE during an acute flare (8.38.8 months), in remission (9.4 +/- 11.5 months), or without IBD (10.0 +/- 12.8 months). The rate of VTE recurrences [7.25, 95% confidence interval (CI): 1.46-21.2; 8.84, 95% CI: 3.23-19.2; and 5.85, 95% CI: 5.46-6.26 per 100 patient-years, respectively] and major bleeding (7.25, 95% CI: 1.46-21.2; 2.95, 95% CI: 0.33-10.6; and 4.79, 95% CI: 4.44-5.15, respectively) were similar in all three subgroups. Propensity score matching analysis confirmed the absence of differences in the rate of VTE recurrences (rate ratio: 1.16, 95% CI: 0.54-2.47) or major bleeding (rate ratio: 0.84, 95% CI: 0.31-2.23) between patients with or without IBD.ConclusionTherapeutic anticoagulation for patients with IBD and VTE is as safe and effective as for those with VTE without IBD.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Gastroenterology &amp; Hepatology

ISSN

0954-691X

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

526-530

UT code for WoS article

000429013300005

EID of the result in the Scopus database

2-s2.0-85044954004